| 王 鹏,刘长庭.非小细胞肺癌中microRNA与EGFR-TKI获得性耐药机制的研究进展[J].肿瘤学杂志,2016,22(3):161-166. |
| 非小细胞肺癌中microRNA与EGFR-TKI获得性耐药机制的研究进展 |
| Research Progress in MicroRNA and the Mechanism of Acquired Resistance of EGFR-TKI in Non-small Cell Lung Cancer |
| 投稿时间：2015-08-18 |
| DOI：10.11735/j.issn.1671-170X.2016.03.B001 |
|
 |
| 中文关键词: 非小细胞肺癌 微小RNA（microRNA） 表皮生长因子受体（EGFR） 酪氨酸激酶抑制剂（TKI） 获得性耐药 |
| 英文关键词:non-small cell lung cancer microRNAs epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI) acquired resistance |
| 基金项目: |
|
| 摘要点击次数: 2717 |
| 全文下载次数: 794 |
| 中文摘要: |
| 摘 要：在表皮生长因子受体（epidermal growth factor receptor，EGFR）活化突变的非小细胞肺癌（non-small cell lung cancer，NSCLC）治疗中，EGFR酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）越来越多地应用于临床治疗，但EGFR-TKI获得性耐药不仅使患者疾病进展，更成为制约EGFR-TKI继续使用的瓶颈。微小RNA（microRNA，miRNA）通过与特定miRNA 3’-UTR（非编码区）结合抑制蛋白质表达，参与肿瘤的发生、发展等。最近许多研究表明miRNAs参与EGFR-TKI的耐药，影响肿瘤对EGFR-TKI的敏感性，为NSCLC的治疗提供新方法。文章结合国内外最新报道，对miRNA与 EGFR-TKI获得性耐药之间的关系作一简要综述。 |
| 英文摘要: |
| Abstract：Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI) are increasingly used in the treatment of EGFR active mutant non-small cell lung cancer(NSCLC). The EGFR-TKI acquired resistance not only makes the disease progress，but also becomes the bottleneck of continuation of EGFR-TKI therapy. By binding with specific mRNA 3’-UTR(untranslated region)，microRNAs(miRNAs) can inhibit protein expression，and are involved in tumorigenesis. Recently，many studies have demonstrated that miRNAs involve in EGFR-TKI resistance，which affect the sensitivity of tumor to EGFR-TKI and may provide a new method to the treatment of NSCLC. The latest progress on the relationships between miRNAs and acquired resistance of EGFR-TKI are reviewed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |